Zobrazeno 1 - 10 of 91 pro vyhledávání: '"A.C.M. van den Bergh"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Autor: Andrés Cervantes, H.P. Knol, L. Østergaard, M.L. Lydrup, S.A. Radema, R.F. Schmitz, P. Nieboer, J. Hol, I. Edhemovic, K.C.M.J. Peeters, A. Johnsson, F.J.F. Jeurissen, Pieter J. Tanis, A.C.M. van de Luijtgaarden, P. Quarles an Ufford, H. Kim, Hein Putter, W.A. Bleeker, Tone Fokstuen, M E van Leerdam, K. Kovacs, A. Pronk, E.D. Kerver, L.G.H. Dewit, E. Garcia Granero, P.A. Nijenhuis, T. Fokstuen, S. Ottosson, P. Flygare, M.J. Safont, Iris D. Nagtegaal, F. Svendsen Jensen, C. Bratthäll, H.M. Ceha, L. Malmberg, P. Hede, W.M. van der Deure, G. Carlsson, J. Haux, Derk Jan A. de Groot, Esmée A Dijkstra, Renu R. Bahadoer, G.A.P. Nieuwenhuijzen, B. de Valk, B. Lindh, D. Hess, G.L. Beets, J.C. Bernal, A.M.E. Bruynzeel, R.M.P.H. Crolla, C. Kersten, P. Pfeiffer, S. Biondo, M.L. Silviera, Jannet C. Beukema, W.H. Schreurs, O. Hallböök, B.L. Lödén, A. Espí Macías, V. Velenik, L. Österlund, A. Slot, Geke A. P. Hospers, H. de Wilt, A.W.K.S. Marinelli, O. Lundberg, C. Radu, J. die Trill, I. Verbiené, P. Matthiessen, Mathijs P. Hendriks, J.H.M. Bekker, M. Walldén, V. Pachón, H.W. Kapiteijn, J.M. Immink, A. Piwowar, R. Salazar, L. Påhlman, P. Braam, K.E.J. Jensen, S. Festen, O. Mjåland, Elma Meershoek-Klein Kranenbarg, Jaume Capdevila, U. Palenius, K. Villmann, J.J. van der Vliet, Albert J. ten Tije, A. Berglund, Corrie A.M. Marijnen, G. Dafnis, J. Assarsson, J. Capdevila, J.W.T. Dekker, M. Grønlie Guren, G.J. Veldhuis, Q.A.J. Eijsbouts, G.J. Creemers, J.B. Tuynman, C.J.A. Punt, P.H.J.M. Veldman, J. Aparicio, Klaas Havenga, E.D. Geijsen, W.H. Steup, T. Rozema, K. Smedh, Lennart Blomqvist, J. de Boer, Cornelis J.H. van de Velde, S. Jangmalm, J.W.P. Vanstiphout, T.C. Stam, A.C.M. van den Bergh, Annet G H Roodvoets, Janet R. Vos, E.J.M. Siemerink, R.J.I. Bosker, Bengt Glimelius, A. Cervantes, E. Espin, Per Nilsson, A.J. Ten Tije, Ibrahim Edhemovic, Boudewijn van Etten, M. Tascilar, A.N. Nesbakken, G.A. Patijn, O. Reerink, Regina G. H. Beets-Tan, S. Skullman, H. Hörberg, P. Parinkh, G. Svaninger, M.B. Polée, D. Ten Bokkel Huinink, C. Hoff, A.F.T. Olieman, H. van den Berg, F.P. Peters, Torbjörn Holm, J.M. van Rooijen, M.P. Hendriks, J. Benedik, J.H. Svensson, A.L.T. Imholz
Publikováno v: Lancet Oncology, 22, 29-42
Lancet Oncology, 22(1), 29-42. ELSEVIER SCIENCE INC
the RAPIDO collaborative investigators 2021, ' Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 22, no. 1, pp. 29-42 . https://doi.org/10.1016/S1470-2045(20)30555-6
The Lancet Oncology, 22(1), 29-42. ELSEVIER SCIENCE INC
The Lancet. Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Lancet Oncology, 22, 1, pp. 29-42
The Lancet Oncology, 22(1), 29-42. ELSEVIER
The Lancet Oncology, 22(1), 29-42. Lancet Publishing Group
lancet oncology, 22(1), 29-42. Lancet Publishing Group
BACKGROUND: Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d055e24de581f7d953a2dafec480d7
https://doi.org/10.1016/s1470-2045(20)30555-6
Zobrazit plný text záznamu
4
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands
Autor: Winald R. Gerritsen, A.C.M. van den Bergh, Inge M. van Oort, Ronald de Wit, Carin A. Uyl-de Groot, Andre M. Bergman, Malou C.P. Kuppen, Reindert J.A. van Moorselaar, Hans M. Westgeest, Jules Lavalaye, Metin Tascilar, Alfons J.M. van den Eertwegh, Diederik M. Somford, Niven Mehra, Katja K.H. Aben
Publikováno v: Clinical genitourinary cancer, 20(1), 43-52. CIG MEDIA GROUP, LP
Clinical Genitourinary Cancer, 20(1), 43-52. Elsevier
Clinical Genitourinary Cancer, 20, 43-52
Clinical Genitourinary Cancer, 20, 1, pp. 43-52
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Tascilar, M, Mehra, N, Lavalaye, J, Somford, D M, Aben, K K H, Bergman, A M, de Wit, R, van den Bergh, A C M, de Groot, C A U & Gerritsen, W R 2022, ' Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population : Results From the CAPRI-Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 20, no. 1, pp. 43-52 . https://doi.org/10.1016/j.clgc.2021.10.008
Contains fulltext : 248303.pdf (Publisher’s version ) (Open Access) BACKGROUND: Patients with metastatic castration resistant prostate cancer (mCRPC) are at risk of symptomatic skeletal events (SSE). Bone health agents (BHA, ie bisphosphonates and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27d177b59c6e2b3659b939a21de276f6
https://research.rug.nl/en/publications/6aff08ca-2583-4fbf-80f0-7e6b97065874
Zobrazit plný text záznamu
5
Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry
Autor: Diederik M. Somford, Reindert J.A. van Moorselaar, Carin A. Uyl-de Groot, Ronald de Wit, Laurent M.C.L. Fossion, Niven Mehra, Hans M. Westgeest, Addy C. M. van de Luijtgaarden, Juleon L.L.M. Coenen, N.I. Weijl, Maud M. Geenen, Winald R. Gerritsen, Agnes J. van de Wouw, A.C.M. van den Bergh, Mathijs P. Hendriks, Marco B. Polee, Alphonsus J. M. van den Eertwegh, Andre M. Bergman, Malou C.P. Kuppen, Inge M. van Oort, Daan ten Bokkel Huinink
Publikováno v: European urology oncology, 4(4), 618-627. De Tijdstroom/Elsevier
European Urology Oncology, 4, 618-627
European urology oncology, 4, 618-627. Elsevier
Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005
European Urology Oncology, 4, 4, pp. 618-627
European Urology Oncology, 4(4), 618-627. Elsevier BV
Background: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI + P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5688ade1d20f2f2f131d73a057ff810
https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028
Zobrazit plný text záznamu
6
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands
Autor: Haiko J. Bloemendal, Niven Mehra, Marco B. Polee, Joan van den Bosch, Alphonsus J. M. van den Eertwegh, Carin A. Uyl-de Groot, Daan ten Bokkel Huinink, H. P. (Pieter) van den Berg, Andre M. Bergman, Inge M. van Oort, Malou C.P. Kuppen, Addy C. M. van de Luijtgaarden, Laurent M.C.L. Fossion, Mathijs P. Hendriks, Juleon L.L.M. Coenen, Winald R. Gerritsen, Hans M. Westgeest, A.C.M. van den Bergh, Ronald de Wit, N.I. Weijl
Publikováno v: Clinical Genitourinary Cancer, 17, 5, pp. e946-e956
Clinical Genitourinary Cancer, 17(5), E946-E956. Elsevier
Clinical genitourinary cancer, 17(5), E946-E956. CIG MEDIA GROUP, LP
Westgeest, H M, Kuppen, M C P, van den Eertwegh, A J M, de Wit, R, Coenen, J L L M, van den Berg, H P, Mehra, N, van Oort, I M, Fossion, L M C L, Hendriks, M P, Bloemendal, H J, van de Luijtgaarden, A C M, ten Bokkel Huinink, D, van den Bergh, A C M, van den Bosch, J, Polee, M B, Weijl, N, Bergman, A M, Uyl-de Groot, C A & Gerritsen, W R 2019, ' Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands ', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956 . https://doi.org/10.1016/j.clgc.2019.05.018
Clinical Genitourinary Cancer, 17(5), e946-e956. Elsevier
Clinical Genitourinary Cancer, 17, e946-e956
In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c55db3d2d7c2abd92a4b76a9b4278c5e
https://doi.org/10.1016/j.clgc.2019.05.018
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Symptomatic skeletal related events (SSE) and SSE-free-survival in real world castration-resistant prostate cancer (CRPC) patients: Results from CAPRI
Autor: H.M. Westgeest, Jules Lavalaye, Andre M. Bergman, Katja K.H. Aben, C.A. Uyl-de Groot, I.M. van Oort, Jules L.L.M. Coenen, Malou C.P. Kuppen, Winald R. Gerritsen, A.C.M. van den Bergh, J. Van Moorselaar, A.J.M. van den Eertwegh, R. Somford, Niven Mehra
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii282-viii283. Oxford University Press
Kuppen, M, Westgeest, H M, van den Eertwegh, A J M, Van Moorselaar, J, Mehra, N, van Oort, I, van den Bergh, A C M, Coenen, J L, Aben, K K H, Somford, R, Lavalaye, J, Bergman, A, Uyl-de Groot, C A & Gerritsen, W R 2018, ' Symptomatic skeletal related events (SSE) and SSE-free-survival in real world castration-resistant prostate cancer (CRPC) patients : Results from CAPRI ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii282-viii283 . https://doi.org/10.1093/annonc/mdy284.024
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81819825164ab7703f93a1d28aada53
https://research.vumc.nl/en/publications/2f07f8d7-bf5f-44a7-b51d-4f9b904abfa4
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje